ReviewSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2012
Thrombosis, cancer and renal insufficiency: low molecular weight heparin at the crossroads.
Review in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 33 citations in OpenAlex.
- Warfarin-GPRP: Development and Evaluation of a Novel Warfarin-Based Peptide Conjugate for Enhanced Anticoagulant Activity.ACS omega · 2026Article
- Approach to Thromboprophylaxis for Prevention of Venous Thromboembolism in COVID-19: Global Updates and Clinical Insights from India.Clinics and practice · 2022Review
- Cancer-Associated Thrombosis: Not All Low-Molecular-Weight Heparins Are the Same, Focus on Tinzaparin, A Narrative Review.International journal of clinical practice · 2022Review
- Article
- Construction and Validation of a Nomogram for Predicting the Risk of Deep Vein Thrombosis in Hepatocellular Carcinoma Patients After Laparoscopic Hepatectomy: A Retrospective Study.Journal of hepatocellular carcinoma · 2021Article
- Current Management of Cancer-associated Venous Thromboembolism: Focus on Direct Oral Anticoagulants.Journal of Korean medical science · 2019Review
- Anticoagulation in Cancer Patients: a Summary of Pitfalls to Avoid.Current oncology reports · 2019Review
- Characteristics and Impacts of Venous Thromboembolism in Patients with Hepatocellular Carcinoma.Journal of gastrointestinal cancer · 2018Article
- Performance of Khorana Risk Score for Prediction of Venous Thromboembolism in Patients With Hepatocellular Carcinoma.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis · 2018Article
- The Role of Pulmonary Veins in Cancer Progression from a Computed Tomography Viewpoint.Journal of oncology · 2016Article
- Venous thromboembolism risk factors in Chinese non-small cell lung cancer patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2015Article
- Pulmonary Venous Obstruction in Cancer Patients.Journal of oncology · 2015Article
- What is the Best Treatment for a Cancer Patient with Thrombosis?Clinical Medicine Insights. Oncology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVenous thromboembolism (VTE) and renal insufficiency are common in cancer patients. Prompt treatment is necessary to reduce the high rates of VTE-related mortality and morbidity. VTE prophylaxis is underused in cancer patients. We review current recommendations for the treatment and prevention of VTE in cancer patients and discuss low molecular weight heparin (LMWH) use in cases of renal failure.
designThis study is a retrospective literature review.
resultsThere are few published recommendations for LMWH use in cancer patients with renal insufficiency. Treatment guidelines largely follow recommendations for other patients with renal failure. Enoxaparin therapy is complicated by the need for regular monitoring of renal function and anti-Xa levels and for dosage adjustment to prevent bleeding. Few data are available to support the systematic use of dalteparin. Tinzaparin is least likely to bioaccumulate in patients with renal failure.
conclusionVTE is the second most common cause of death in cancer patients. Renal insufficiency is present in 50-60 % of cancer patients. Data from renal patients suggest that tinzaparin may be safe and effective for VTE treatment and prevention in cancer patients with renal failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.